Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · IEX Real-Time Price · USD
1.080
+0.030 (2.86%)
Apr 25, 2024, 4:00 PM EDT - Market closed
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG.
The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | Canada |
| Founded | 1998 |
| IPO Date | Nov 8, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Dr. Matthew C. Coffey M.B.A., Ph.D. |
Contact Details
Address: 804, 322 - 11 Avenue Sw Calgary, A0 T2R 0C5 Alberta, Canada | |
| Phone | 4036707380 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001129928 |
| CUSIP Number | 682310875 |
| ISIN Number | CA6823108759 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Matthew C. Coffey M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Kirk J. Look C.A., CA | Chief Financial Officer |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development |
| Amy Goodowitz Levin | Vice President of Clinical Operations |
| Jon Patton | Director of Investor Relations and Communication |
| John Mark Lievonen BBA, C.M., FCA, LLD, MBA | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 12, 2024 | 6-K | Report of foreign issuer |
| Apr 11, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 12, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 7, 2024 | 6-K | Report of foreign issuer |
| Mar 5, 2024 | 6-K | Report of foreign issuer |
| Mar 4, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | 6-K | Report of foreign issuer |